Moreover, one study found that a pulmonary MEC cell line with wild-type EGFR showed more sensitivity to gefitinib when compared to NSCLC cell lines with wild-type EGFR [88]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.